Accenture Named a Leader in Life Sciences Digital Services by Independent Research Firm, Everest Group

Accenture has been named a Leader in life sciences digital services in a new report from Everest Group, a leading independent research firm.

The report, “Life Sciences Digital Services – Service Provider Landscape with Services PEAK Matrix® Assessment 2019,” examines the changing dynamics of the life sciences digital services landscape, including industry and market trends, and compares 23 internet technology vendors against the criteria most important for life sciences companies to consider when selecting a service provider.

Accenture emerged as a Leader in the report due to the company’s “consultative approach with clients to create downstream implementation opportunities” and its ability to “help frame long-term digital strategies.” The report also notes Accenture’s “investments in innovative constructs, partnerships and alliances” as strengths.

Read More: World’s Largest Blockchain Application Competition ‘Klaytn Horizon’ Winners Announced

The report describes a Leader as having a balanced portfolio; able to develop innovative digital use-cases for life sciences firms; and keeping pace with market dynamics through continued investments in technology and services capability development (internal intellectual property and tools, mergers and acquisitions, partnerships, etc.).

“Accenture is committed to supporting clients’ efforts to make a meaningful impact on patients’ lives by helping clients rapidly advance what we call ‘New Science’ — the combination of the best in science with leading-edge technology to improve how medical treatments are discovered, developed and delivered to people around the world,” said Stuart Henderson, who leads Accenture’s Life Sciences group. “Our INTIENT platform, for example, enables life sciences companies to aggregate, analyze and leverage internal and external data, using analytics and artificial intelligence, to improve patient outcomes.”

Read More: MetricStream and the AI Sustainability Center Announce Collaboration to Automate Ethical AI Risk Scanning

Nitish Mittal, Practice Director at Everest Group, said, “Challenges such as the complexity and high cost of drug development and increased time-to-market for drugs confront life sciences enterprises today. To overcome these challenges, enterprises are prioritizing the adoption of digital technologies with a focus on scaling technology proliferation and core business outcomes. Accenture has established itself as a front runner to support large life science customers that prefer service providers to help them achieve digital transformation objectives. Accenture’s proactive investments have helped it generate a balanced portfolio that supports its ability to come up with innovative digital use-cases for life sciences firms.”

Read More: How Conversational AI will Boost the 2020s Economy